Fulgent reiterates 2026 revenue guidance after Q1 revenue beat, EPS miss

 

Fulgent reiterates 2026 revenue guidance after Q1 revenue beat, EPS miss, repurchases 10% of shares, expects delayed $106M federal income tax refund, bolstering liquidity

• Q1 2026 revenue $71.1M, down 3.2% YoY, hurt by largest customer insourcing but above estimates.
• Non-GAAP EPS -$0.36 in Q1 2026 declined 1000% YoY and missed earnings estimates.
• Q1 non-GAAP gross margin was 32.3%, pressured by lower testing volumes and a claims processing backlog.
• Management reiterated 2026 revenue guidance of $350M and a 39% non-GAAP gross margin outlook.
• Company guides full-year 2026 non-GAAP loss of approximately $46M, or $(1.59) per share, cut solely from share-count reduction.
• Acquisition of Bako and StrataDx adds $53M of expected 2026 revenue and helps diversify customer concentration risk.
• Q2–Q4 2026 revenue projected above $90M per quarter, with margins improving as the claims backlog clears.
• Company repurchased 3.1M shares year-to-date, disclosing $40.1M of stock buybacks in an SEC filing today.
• On Q1 2026 earnings call, management expects delayed $106 million federal income tax refund to bolster its liquidity profile.
• Despite significant repurchases signaling confidence, management expects year-end 2026 cash about $636M and currently holds $605M.
• Therapeutics pipeline progressing: FID-007 completed Phase II, has ASCO oral presentation, with Phase III targeted to start in 2027.
• Main risks include integrating acquisitions, offsetting largest-customer decline, and sustaining high R&D spending levels.
• Main concern remains near-term revenue and margin headwinds from customer insourcing while non-GAAP losses stay sizable.
• Overall a mixed quarter, with largest-customer volume decline offset partly by acquisitions and therapeutics pipeline progress.

https://finviz.com/quote?t=FLGT&p=d

Encompass raises 2026 revenue, EBITDA and EPS guidance on strong demand, better labor efficiency

 

Encompass Health beats Q1 2026 estimates and raises 2026 revenue, EBITDA and EPS guidance on strong demand, better labor efficiency

• Raised 2026 EPS guidance to $5.89–$6.11 and revenue outlook to $6.38–$6.47B.
• 2026 guidance raised for revenue, EBITDA, and EPS on Q1 strength, robust demand and improved demand visibility.
• Q1 2026 non-GAAP EPS of $1.60 increased 17% year over year.
• Q1 revenue rose 9% to $1.59B; adjusted EBITDA grew faster at 11.2%.
• Total discharges grew 4.3%, same-store 1.6%, with 3.7% net revenue per discharge growth.
• High occupancy, averaging 78.7% with 35% of hospitals above 90%, is constraining some growth.
• Labor environment improving: RN turnover at decade-plus low, premium labor spend down 9.4%.
• Strong quarter driven by robust inpatient rehab demand, firm pricing and better labor efficiency across facilities.
• Regulatory overhang persists from TEAM, RCD expansion, and CMS payment model RFI, adding uncertainty to the outlook.
• Medicare Advantage remains challenging, though admit-and-appeal pilot is showing early positive traction.
• Capex stepping up toward approximately 15% of revenue to relieve capacity constraints and support growth.
• Free cash flow strong at $194M; company repurchased $71.6M of stock and maintained dividend.
• CMS proposes 2.4% IRF rate update from October 2026, seen as a modest tailwind if finalized.
• Main concern: high occupancy and evolving Medicare Advantage and regulatory dynamics could constrain or pressure growth.

https://finviz.com/quote?t=EHC&p=d

Vanda launches NEREUS motion sickness drug commercially in U.S. with DTC platform

• NEREUS (tradipitant), an FDA‑approved treatment for motion sickness, is now available nationwide across the U.S.
• Vanda launched a new direct‑to‑consumer ordering platform to support NEREUS access for patients.
• Company disclosed cash‑pay pricing for NEREUS as part of the commercial rollout.

https://finviz.com/quote?t=VNDA&p=d

Iradimed beats Q1 2026 estimates as 3870 pump outperforms, reaffirms 2026 guidance

 

Iradimed beats Q1 2026 estimates as 3870 pump outperforms, reaffirms 2026 guidance

• Q1 2026 non-GAAP EPS $0.49 (+17% YoY) and revenue $22.0M (+13% YoY) both beat analyst estimates.
• Q1 revenue $22m up 13% YoY; EPS $0.45 up 22%, strong profitability.
• Pump revenue up 28% YoY, monitor revenue up 9%, disposables flat, ferromagnetic detection revenue $0.6m.
• 3870 pump ASP running ~20% above legacy model versus 10–14% initial expectations.
• Majority of early 3870 orders are quad systems, effectively doubling pump channels per site.
• Q2 revenue guided to $20–21m, below Q1 due to controlled 3870 production ramp.
• Full-year 2026 guidance reaffirmed: revenue $91–96m, GAAP EPS $1.90–2.05, non-GAAP $2.06–2.21.
• Gross margin improved to 77% from 76%; operating income up 33% to $7.2m.
• Strong balance sheet with $56.4m cash and $7.6m free cash flow; continuing $0.20 quarterly dividend.
• Board declares cash dividend of $0.20 per share following Q1 2026 results.
• Management highly confident in large multi-year 3870 replacement opportunity driving higher pump channel volumes.
• Key risk is execution on manufacturing and supply-chain ramp to meet strong 3870 demand.
• Main concern: execution risk in ramping 3870 production while legacy pump revenue declines during the transition.
• Strong quarter, driven by robust pump growth and better-than-expected 3870 pricing and mix.

https://finviz.com/quote?t=IRMD&p=d

Iran said to ease terms in bid to revive US talks

 The new proposal submitted by Iran to Washington aimed at reviving talks to end the war drops Tehran's earlier demand that the US end its blockade before negotiations resume, The Wall Street Journal reported on Friday, citing people familiar with the matter.

Instead, Tehran is offering to discuss conditions for reopening the Strait of Hormuz at the same time as US guarantees to halt attacks and unwind the blockade of Iranian ports, according to the report.

Iran has indicated it could attend talks in Pakistan by early next week if Washington accepts the proposal. However, the two sides remain far apart on Hormuz and Iran's nuclear program, with the US seeking a long enrichment halt and the transfer of highly enriched uranium stockpiles.

https://breakingthenews.net/Article/Iran-said-to-ease-terms-in-bid-to-revive-US-talks/66203003

Streeting said ready to challenge Starmer next week

 United Kingdom Health Secretary Wes Streeting could launch a leadership challenge against Prime Minister Keir Starmer as soon as next Friday, the day after local elections scheduled for May 7, The Telegraph reported on Friday.

Streeting has reportedly secured backing from more than 81 Labour Members of Parliament (MPs), the number required to trigger a contest, with allies urging him to act quickly after the vote. Meanwhile, a spokesperson said Streeting "supports the Prime Minister" and is "completely focused on his job."

Starmer is facing mounting pressure as a widening scandal over Peter Mandelson's ties to late sex offender Jeffrey Epstein deepens after he was appointed as the UK's ambassador to the United States.

https://breakingthenews.net/Article/Streeting-said-ready-to-challenge-Starmer-next-week/66203186

GameStop preparing offer for eBay, WSJ reports

GameStop is preparing to make an ‌offer for eBAY, the ‌Wall Street Journal reported on ​Friday, citing people familiar with the matter.

Shares of eBay, which has a market capitalization ‌of about $46 ⁠billion, were up about 9% in extended ⁠trading on Friday.

Shares of GameStop, which has a ​market capitalization ​of nearly $12 ​billion, were ‌up about 3%.

GameStop has been quietly building a stake in eBay's shares ahead of a potential offer, the ‌report said. It ​could submit an ​offer ​for eBay as soon ‌as later this ​month.

GameStop and ​eBay did not immediately respond to Reuters' requests ​for ‌comment.

https://finance.yahoo.com/markets/stocks/articles/gamestop-preparing-offer-ebay-wsj-212703455.html